MedTrace Logo

[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis

NCT07232459 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2025-11-18

No results posted yet for this study

Summary

\[18F\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\[18F\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \[18F\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \[18F\]FT8 PET imaging in human subjects.

Conditions

  • Amyloid
  • Cardiac Amyloidosis
  • Amyloidosis
  • Healthy Subjects

Interventions

DIAGNOSTIC_TEST

[18F]FT8

Each subject will receive a single intravenous injection of \[18F\]FT8 and will undergo PET imaging at a specified time.

Sponsors & Collaborators

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Tianjin Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-21
Primary Completion
2028-07-20
Completion
2028-12-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07232459 on ClinicalTrials.gov